CN Patent

CN114286820A — 酶抑制剂

Assigned to Kalvista Pharmaceuticals Ltd · Expires 2022-04-05 · 4y expired

What this patent protects

本发明提供式(I)化合物：包含此类化合物的组合物；此类化合物在疗法中的用途；以及使用此类化合物治疗患者的方法；其中A、B和n如本文所定义。

USPTO Abstract

本发明提供式(I)化合物：包含此类化合物的组合物；此类化合物在疗法中的用途；以及使用此类化合物治疗患者的方法；其中A、B和n如本文所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN114286820A
Jurisdiction
CN
Classification
—
Expires
2022-04-05
Drug substance claim
No
Drug product claim
No
Assignee
Kalvista Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.